Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Matinas Biopharma Holdings, Inc. (MTNB) had Consolidated Net Income/Loss of $-1.92M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-1.92M |
|
-- |
|
-- |
|
$1.94M |
|
$-1.94M |
|
$0.01M |
|
$-1.92M |
|
$-1.92M |
|
$-1.92M |
|
$-1.92M |
|
|
Consolidated Net Income/Loss |
$-1.92M |
$-1.92M |
|
$-1.94M |
|
$-1.86M |
|
6.41M |
|
6.41M |
|
$-0.30 |
|
$-0.30 |
|
| Balance Sheet Financials | |
$2.81M |
|
$0.14M |
|
$3.06M |
|
$5.87M |
|
$2.13M |
|
$0.01M |
|
$0.73M |
|
$2.85M |
|
$3.02M |
|
$3.02M |
|
$3.02M |
|
6.41M |
|
| Cash Flow Statement Financials | |
$-1.60M |
|
-- |
|
-- |
|
$4.25M |
|
$2.65M |
|
$-1.60M |
|
$0.11M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.32 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.60M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.57% |
|
-63.57% |
|
-32.70% |
|
-63.46% |
|
$0.47 |
|
$-0.25 |
|
$-0.25 |
|